IDEAYA Biosciences (IDYA) Operating Income (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Operating Income of -$108.5 million for Q1 2026, down 14.78% sequentially from -$94.6 million in Q4 2025, and down 28.62% YoY from -$152.1 million in Q1 2025.
IDEAYA Biosciences (IDYA) Operating Income (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Operating Income for 9 years, with the latest figure at -$108.5 million in Q1 2026.
- Quarterly Operating Income fell 28.62% year-over-year to -$108.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$183.5 million (up 49.09% YoY) and the FY2025 annual result came in at -$159.3 million, up 51.28% from the prior year.
- Operating Income retreated to -$108.5 million in Q1 2026 per IDYA's latest filing, from -$94.6 million in the prior quarter.
- Over five years, Operating Income peaked at $108.5 million in Q3 2025 and troughed at -$144.1 million in Q4 2024.
- A 5-year average of -$46.6 million and a median of -$41.9 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2025: Operating Income slumped 5179.7% in 2023, then jumped 262.13% in 2025.
- Over 5 years, Operating Income stood at -$26.4 million in 2022, then tumbled by 58.52% to -$41.9 million in 2023, then slumped by 243.87% to -$144.1 million in 2024, then surged by 34.39% to -$94.6 million in 2025, then decreased by 14.78% to -$108.5 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$108.5 million, -$94.6 million, and $108.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | -122.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -122.29 Mn |
| Mar 31, 2026 | -108.54 Mn |
| Dec 31, 2025 | -94.57 Mn |
| Sep 30, 2025 | 108.45 Mn |
| Jun 30, 2025 | -88.81 Mn |
| Mar 31, 2025 | -84.39 Mn |
| Dec 31, 2024 | -144.14 Mn |
| Sep 30, 2024 | -66.89 Mn |
| Jun 30, 2024 | -64.93 Mn |
| Mar 31, 2024 | -51.02 Mn |
| Dec 31, 2023 | -41.92 Mn |
| Sep 30, 2023 | -33.53 Mn |
| Jun 30, 2023 | -32.71 Mn |
| Mar 31, 2023 | -26.28 Mn |
| Dec 31, 2022 | -26.44 Mn |
| Sep 30, 2022 | 660,000.00 |
| Jun 30, 2022 | -22.50 Mn |
| Mar 31, 2022 | -14.22 Mn |
| Dec 31, 2021 | -18.37 Mn |
| Sep 30, 2021 | -11.71 Mn |